Sunil Paliwal
Teaching Associate Professor
Charles V. Schaefer, Jr. School of Engineering and Science
Department of Chemistry and Chemical Biology
Education
- PhD (1996) University of Pittsburgh (Organic Chemistry)
- MS (1989) Indian Institute of Technolgy (Chemistry)
- BS (1987) Hindu College (Chemistry)
Research
At Stevens, Dr. Paliwal's research is focused on Computational guided drug development, virtual screening, and developing molecules to treat infectious disease such as COVID-19.
Experience
Dr. Paliwal has 15 years experience as a medicinal chemist and project leader performing research in drug discovery for Schering-Plough Research Institute and at Merck where he was Director of Exploratory Medicinal Chemistry. His expertise is in developing small molecules to treat oncology, neurological, cardiovascular and inflammation diseases.
Dr. Paliwal’s preclinical discovery includes leading teams to discover early drug hits from high-throughput screening (HTS) involving the screening of millions of compounds, optimization of hits and developing program leads through evaluations of chemical structure and biological data to develop key structural-activity-relationships (SAR). Dr. Paliwal’s research experience also include optimization of the DMPK and biological data of the leads to deliver clinical compounds with optimal DMPK/pharmacological properties. He is co-inventor of a drug (Varubi®) and has progressed two other compounds into clinic to treat cancer and neurological diseases.
Dr. Paliwal’s preclinical discovery includes leading teams to discover early drug hits from high-throughput screening (HTS) involving the screening of millions of compounds, optimization of hits and developing program leads through evaluations of chemical structure and biological data to develop key structural-activity-relationships (SAR). Dr. Paliwal’s research experience also include optimization of the DMPK and biological data of the leads to deliver clinical compounds with optimal DMPK/pharmacological properties. He is co-inventor of a drug (Varubi®) and has progressed two other compounds into clinic to treat cancer and neurological diseases.
Institutional Service
- Graduate Education Committee Member
- Graduate Education Committee Member
Consulting Service
Provided medicinal chemistry expertise to biotech and academic institutions.
Innovation and Entrepreneurship
Co-inventor of the drug (Varubi®).
Professional Societies
- ACS – American Chemical Society Member
Patents and Inventions
Mcelroy, W.; Li, G.; Ho, G.; Zheng, T.; Paliwal, S.; Seganish, W.M.; Tulshian, D.; Lampe, J.; Methot, J.L.; Zhou, H.; Altman, M.D.; Zhu, L.“Amidopyrazole inhibitors of interleukin receptor-associated kinases” WO 2012129258.
Paliwal, S.; Tsui H.-C.; Gao, X.; Kim, H.M.; Caplen, M.A.; Fischmann, T.; Duca, J.S. “Novel heteroaryl-carboxamide derivatives as PDK1 inhibitors” WO 2012058176.
Tsui, H.-C.; Paliwal, S.; Gao, X.; Hyunjin, H. M.; Doll, R.J. “Novel thiazole-carboxamide derivatives as PDK1 inhibitors” WO 2012058174.
Tsui, H.-C.; Paliwal, S.; Kim, H.M.; Kerekes, A.; Caplen, M.A.; Esposite, S.J.; Mckittrick, B.A.; Fischmann, T.O.; Doll, R.; Rainka, M.P. “N-Phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 (PDK-1)” WO 2011149874.
Paliwal, S.; Tsui H.-C.; Gao, X.; Kim, H.M.; Caplen, M.A.; Fischmann, T.; Duca, J.S. “Novel heteroaryl-carboxamide derivatives as PDK1 inhibitors” WO 2012058176.
Tsui, H.-C.; Paliwal, S.; Gao, X.; Hyunjin, H. M.; Doll, R.J. “Novel thiazole-carboxamide derivatives as PDK1 inhibitors” WO 2012058174.
Tsui, H.-C.; Paliwal, S.; Kim, H.M.; Kerekes, A.; Caplen, M.A.; Esposite, S.J.; Mckittrick, B.A.; Fischmann, T.O.; Doll, R.; Rainka, M.P. “N-Phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 (PDK-1)” WO 2011149874.